- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03499327
Human Intervention Study to Increase 25-hydroxyvitamin D Levels (WeKo)
Human Intervention Study to Increase 25-hydroxyvitamin D Levels by Regular Consumption of Wheat Germ Oil (UV-treated) vs. Wheat Germ Oil Untreated (Control)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The interventional study in parallel design will evaluate the effectiveness and potential of a daily consumption of wheat germ oil (UV treated vs. untreated) to increase plasma vitamin D levels in humans.
Wheat germ oil is naturally rich in vitamin D precursors (ergosterol and 7-dehydrocholesterol), which are converted into vitamin D2 and vitamin D3 by a defined UV light irradiation for the present study.
Half of the participants will consume UV-treated wheat germ oil (intervention) and the other part will consume traditional wheat germ oil (untreated, control). The subjects will consume 10 ml of wheat germ oil per day over an entire period of 6 weeks (no follow-up).
On the basis of the planned human intervention study (randomized, single-blind, parallel design) it will be investigated to what extent a regular consumption of wheat germ oil (UV-treated) can contribute to the increase of plasma 25 (OH) D levels.
The comparison is made against the intake of traditional (untreated) wheat germ oil (control).
The study fits with the strategy of the Competence Cluster for Nutrition and Cardiovascular Health (nutriCARD), Halle-Jena-Leipzig, Germany (www.nutriCARD.de) and the study collaborators are active members of the nutriCARD cluster.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Thuringia
-
Jena, Thuringia, Germany, 07743
- Friedrich-Schiller-University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- healthy subjects
- plasma 25(OH) vitamin D < 50 nmol/l
- nutritional habits: western diet
Exclusion Criteria:
- intake of lipid-lowering medications
- gastrointestinal diseases, diabetes mellitus type I and II
- intake of supplements (vitamin D supplements, fish oil capsules, vitamins and minerals) 3 months before and during the study
- relevant food allergies / intolerances
- visit to the solarium (within 4 weeks before beginning of the study and during the study)
- stay in the mountains / skiing (within 4 weeks before beginning of studies and during the study)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Wheat germ oil (UV treated)
|
Wheat germ oil is naturally rich in vitamin D precursors (ergosterol and 7-dehydrocholesterol), which are converted into vitamin D2 and vitamin D3 by a defined UV light irradiation for the present study (wheat germ oil (UV treated). The wheat germ oil (UV treated) is dispensed in dark glass bottles without label. The distinction between the groups is based on the expiration date (08.05.2018 vs. 09.05.2018). The distinction between the groups is not possible for the participants. The daily dosage of wheat germ oil is 10 ml and the study products will be consumed over an entire period of 6 weeks (no follow-up). Recommendation for intake: pure before a main meal. |
Placebo Comparator: Wheat germ oil (untreated)
|
commercial available wheat germ oil The wheat germ oil (untreated) is dispensed in dark glass bottles without label. The distinction between the groups is based on the expiration date (08.05.2018 vs. 09.05.2018). The distinction between the groups is not possible for the participants. The daily dosage of wheat germ oil is 10 ml and the study products will be consumed over an entire period of 6 weeks (no follow-up). Recommendation for intake: pure before a main meal. |
No Intervention: Control
no study products
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vitamin D status
Time Frame: change from baseline after 3 and 6 weeks
|
plasma levels of 25OHD2, 25OHD3 (nmol/l)
|
change from baseline after 3 and 6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood lipids
Time Frame: change from baseline after 3 and 6 weeks
|
total cholesterol, LDL cholesterol, HDL cholesterol, triacylglycerides (mmol/L)
|
change from baseline after 3 and 6 weeks
|
Blood glucose
Time Frame: change from baseline after 3 and 6 weeks
|
fasting blood glucose (mmol/l)
|
change from baseline after 3 and 6 weeks
|
Insulin
Time Frame: change from baseline after 3 and 6 weeks
|
insulin (units/ml)
|
change from baseline after 3 and 6 weeks
|
soluble Klotho (sKlotho)
Time Frame: change from baseline after 3 and 6 weeks
|
sKlotho is a component of the FGF23 system and is associated with longevity
|
change from baseline after 3 and 6 weeks
|
Fibroblast growth factor 23 (FGF23)
Time Frame: change from baseline after 3 and 6 weeks
|
FGF23 is a regulator of vitamin D metabolism and also a risk factor for heart failure
|
change from baseline after 3 and 6 weeks
|
Fatty acid distribution (erythrocytes)
Time Frame: change from baseline after 3 and 6 weeks
|
fatty acid distribution in erythrocyte lipids (% fatty acid methyl ester)
|
change from baseline after 3 and 6 weeks
|
Vitamin D forms 1
Time Frame: change from baseline after 3 and 6 weeks
|
1,25(OH)2D2 (nmol/l)
|
change from baseline after 3 and 6 weeks
|
Vitamin D forms 2
Time Frame: change from baseline after 3 and 6 weeks
|
1,25(OH)2D3 (nmol/l)
|
change from baseline after 3 and 6 weeks
|
Vitamin D forms 3
Time Frame: change from baseline after 3 and 6 weeks
|
24,25(OH)2D (nmol/l)
|
change from baseline after 3 and 6 weeks
|
Vitamin D forms 4
Time Frame: change from baseline after 3 and 6 weeks
|
20(OH)D (nmol/l)
|
change from baseline after 3 and 6 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- H5_18
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vitamin D3 Deficiency
-
Gdansk University of Physical Education and SportCompleted
-
Medical University of South CarolinaW.K. Kellogg FoundationCompletedVitamin D3 DeficiencyUnited States
-
Martin-Luther-Universität Halle-WittenbergGerman Federal Ministry of Education and ResearchCompletedDeficiency of Vitamin D3Germany
-
Pauls Stradins Clinical University HospitalCompletedVitamin D3 DeficiencyLatvia
-
University of California, San FranciscoCompleted
-
University of PaviaIstituti Clinici Scientifici Maugeri SpAUnknownVitamin D Deficiency | Vitamin D3 Deficiency | Vitamin DItaly
-
Princess Nourah Bint Abdulrahman UniversityUniversity of ConnecticutCompletedDeficiency of Vitamin D3
-
Tianjin Medical University Cancer Institute and...Unknown
-
Akdeniz UniversityCompletedInfertility | Vitamin D Deficiency | Infertility, Female | Vitamin D3 DeficiencyTurkey
-
Instituto Nacional de Salud Publica, MexicoDSM Nutritional Products, Inc.CompletedVitamin D Deficiency | 25-Hydroxyvitamin D3 Deficiency, SelectiveMexico
Clinical Trials on Wheat germ oil (UV treated)
-
Texas Woman's UniversityCompleted
-
IRCCS Eugenio MedeaDMF srl (Dietetic Metabolic Food)CompletedAttention Deficit Hyperactivity DisorderItaly
-
Universidade do PortoCenter for Health Technology and Services Research; Project VALORINTEGRADOR...CompletedHealthy VolunteersPortugal
-
Southeast University, ChinaZhongda Hospital; Chinese Nutrition SocietyActive, not recruitingMetabolic Diseases | Dyslipidemias | Oxidative Stress | Immune System Disorder | Fatty Acid Metabolism DisorderChina
-
Azienda di Servizi alla Persona di PaviaCompletedAthletes | Sports
-
University of California, DavisNational Cancer Institute (NCI)RecruitingAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Clinical Stage III Cutaneous Melanoma... and other conditionsUnited States
-
Western Michigan UniversityGlaxoSmithKlineCompletedMuscle Inflammation | Muscle DamageUnited States
-
Soroka University Medical CenterUnknownSecond Stage of LaborIsrael
-
Sheba Medical CenterUnknownHormone Refractory Prostate CancerIsrael
-
University of MilanCompleted